Folate status and the safety profile of antifolates

Seminars in Oncology

Volumn 29, Issue 2 SUPPL. 5, 2002, Pages 3-7

  Calvert, Hilary ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; LOMETREXOL; METHOTREXATE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; RALTITREXED;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; DIARRHEA; DRUG SAFETY; HUMAN; INFECTION; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0036261858     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(02)70209-1     Document Type: Article

References (33)

1. Temporary remissions in acute leukaemia in children produced by folic acid antagonist 4-amino pteroyl-glutamic acid (aminopterin)
2. Reversal of aminopterin toxicity by water-soluble cuprodihyrdoporphyrins (chloresium)
3. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity
4. The cellular pharmacology of methotrexate
5. Folic acid supplements in vitamin tablets: A determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia
6. The effect of reduced derivatives of folic acid on the toxicity and antileukaemic effect of methotrexate in mice
7. Antimetabolite-metabolite combination in cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular citrovorum factor therapy in human cancer
8. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid
9. Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer
10. An update on thymidylate synthase inhibitors
11. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
12. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
13. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
14. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer
15. Phase I clinical trial of LY264618 (dideazatetrahydrofolic acid, DDATHF)
16. Phase I study of (6R)-5,10-dideazatetrahydrofolate: A folate antimetabolite inhibitory to de novo purine synthesis
17. Phase I and clinical pharmacologic study of LY264618, 5-10-dideazatetrahydrofolate
18. Augmentation of the therapeutic activity of lometrexol [(6-R)5,10-dideazatetra hydrofolate] by oral folic acid
19. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation
20. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid
21. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
22. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer
23. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs
24. MTA, a novel multitargeted antifolate, for preclinical to phase I and beyond: Summary and conclusions
25. Overview of phase II trials of MTA in solid tumors
26. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies
27. Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity
28. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite
29. Efficacy and toxicity of pemetrexed disodium (Alimta) with folic acid (FA) in gastric cancer
30. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days
31. A phase II trial of nolatrexed dihydrochloride in patients with advanced hepato-cellular carcinoma
32. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514
33. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials